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Genes that encode killer Ig-like receptors (KIRs) and their HLA class I ligands segregate independently; thus, some individuals may
express an inhibitory KIR gene but not its cognate ligand. We hypothesised that these patients with KIR–HLA receptor–ligand
mismatch have a low risk of relapse after an autologous haematopoietic stem cell transplantation (HCT). Sixteen consecutive patients
with lymphoma or solid tumour were enrolled onto a prospective study. They received high-dose busulphan and melphalan followed
by autologous CD133
þ HCT. We found that 8 of the 16 patients experienced disease progression after autologous HCT, including
5 of the 6 patients (83%) with no inhibitory KIR–HLA mismatch and 3 of the 6 patients (50%) with 1 mismatched pair; none of the 4
(0%) patients with 2 mismatched pairs experienced disease progression. Survival analyses showed that inhibitory KIR–HLA mismatch
was the only significant prognostic factor (P¼0.01). The potential applicability of the receptor–ligand mismatch model to autologous
HCTs and to patients with lymphoma or solid tumour is clinically significant because of the prevalence of the HCT procedure.
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Human NK cells are regulated by killer Ig-like receptors (KIRs)
that recognise specific groups of HLA class I alleles (Lanier, 2005).
Both KIRs and their HLA ligands exhibit tremendous population
diversity, and the KIR genes on chromosome 19 and HLA genes on
chromosome 6 segregate independently (Hsu et al, 2002; Parham,
2005). Thus, many individuals have an inhibitory KIR gene but
not its corresponding ligand, while others may have a certain
KIR ligand but not its corresponding KIR (Leung et al, 2004;
Parham, 2005).
In corroboration with these genetic findings, we found that the
risk of relapse after haploidentical haematopoietic stem cell
transplantation (HCT) in patients with haematologic malignancies
was best predicted by a model taking into consideration the
expression of inhibitory KIRs on the donor NK cells and the
absence of corresponding KIR ligands in the recipient’s HLA
repertoire (a KIR–HLA receptor–ligand mismatch model) (Leung
et al, 2004). For those HCTs in which neither the donor nor the
recipient had the cognate ligand for the donor’s inhibitory KIRs,
the patients were found to be at low risk of relapse. Indeed,
autoreactive NK cell clones, which are KIR2DL2/2DL3
þ, 2DL1
 ,
and 3DL1
 , have been found in healthy donors who lack HLA-
C
Asn80 (the ligand for KIR2DL2/2DL3), and NK cells from
approximately 50% of these individuals were cytotoxic against
autologous CD34
þ cells (Grau et al, 2004). Therefore, it is logical
to examine the application of the receptor–ligand mismatch model
to autologous HCTs. Because lymphoid leukaemias and solid
tumours such as neuroblastoma are susceptible to KIR–HLA
mismatched NK cell–mediated lysis (Leung et al, 2004, 2005a), we
conducted a prospective study to test the hypothesis that patients
with lymphoma or other solid tumour who receive autologous
HCT have a low risk of relapse if KIR–HLA mismatch(es) is
present.
PATIENTS AND METHODS
Autologous HCT
All patients were enrolled onto an autologous HCT protocol
approved by the Institutional Review Board, and the patients
or their legal guardians gave the written informed consent.
After enrolment, all patients received 10mcgkg
 1 per day
G-CSF for 5 days and then underwent leukapheresis for peripheral
blood stem cell collection. Apheresis products were selected
for CD133
þ cells by using the CliniMACS system for tumour-
cell purging, except for two that had low initial cell
count. Conditioning consisted of busulfan (37.5mgm
 2 per dose
every 6h intravenously for 16 doses) and melphalan (70mgm
 2
per day for 2 days). After stem cell infusion, all patients received
G-CSF, starting 5 days after HCT until ANC was 43000mm
 3 for
two consecutive days.
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All samples were HLA typed by DNA methods as previously
described (Leung et al, 2004). KIR genotyping was performed by
using a genotyping kit from Pel-Freez (now Dynal Biotech,
Invitrogen, Carlsbad, CA, USA) and KIR phenotyping was
determined by flow cytometry analysis, as some of the KIRs may
not be expressed on the cell surface (Leung et al, 2005b). Thus,
a KIR was classified to be positive for a particular patient only
if that KIR gene was tested positive by genotyping and was also
found to be expressed by NK cells in phenotyping. The natural
cytotoxicity of NK cells against K562 cells was determined by a
standard europium release assay with a 40:1 (E:T) cell ratio
(Leung et al, 2004).
Statistical analysis
The cohort was divided into two risk groups based on the
inhibitory KIR–HLA receptor–ligand model and cytotoxicity
model, which have been described previously (Leung et al,
2004). Briefly, a patient was classified as being at low risk by
using the KIR–HLA receptor–ligand model if at least one of the
inhibitory KIR genes expressed on the patient’s NK cells did not
recognise any of the HLA molecules in the patient’s HLA ligand
repertoire. The patients in the low-risk group were then further
categorised by the number of receptor–ligand mismatch pairs.
The hypothesis was that a larger number of KIR–HLA mismatch
pairs would result in greater antitumour activity (Leung et al,
2004). The cytotoxicity model measured the general cytotoxicity
of engrafting NK cells against K562 cells (Leung et al, 2004). The
Perugia’s KIR ligand incompatibility model was not used, because
all grafts were ligand matched with the recipients by definition (ie,
the KIR ligands present in the graft were identical to those in the
patient in all autologous HCTs). Event-free survivals (EFSs) were
estimated and compared by using the method of Kaplan–Meier
and log-rank statistics. Event-free survival was defined as the time
from transplantation to disease progression or death, whichever
occurred first. Because there was no transplant-related mortality,
the EFSs were identical to progression-free survivals and there was
no competing event in the evaluation of the cumulative incidences
of disease progression. Cox’s regression was used to assess hazard
functions. Covariates included receptor–ligand mismatch, type of
malignancy, disease status at the time of HCT, number of CD133
þ
cells in the graft, and natural cytotoxicity. Survivors were censored
at a cut-off of 1 October 2006.
RESULTS
Sixteen consecutive patients in a prospective study underwent
autologous HCT. There was no transplant-related mortality
(Table 1). Eight patients experienced disease progression after
autologous HCT, including five of the six (83%) patients with no
inhibitory KIR–HLA mismatch and three of the six (50%) patients
with one mismatched pair; none of the four (0%) patients with two
mismatched pairs experienced disease progression (Figure 1A).
Survival analyses showed that KIR–HLA mismatch was the only
significant prognostic factor (Figure 1B). The type and status of
malignancy at the time of HCT, the number of CD133
þ cells in the
graft, and the cytotoxicity model measuring the lysis of K562 cells
by engrafting NK cells were not significant prognostic factors
(Table 2). The median time to relapse for the patients in the high-
risk category with no inhibitory KIR–HLA mismatch was only 89
days (Figure 1B), whereas that for patients in the low-risk group
with mismatch has not yet been reached after a median follow-up
of 812 days.
This cohort provides a unique opportunity not only to
investigate the prognostic significance of the KIR–HLA recep-
tor–ligand model, but also to examine the KIR ligand repertoires
of patients with solid malignancy, because HLA typing is typically
not performed for autologous HCTs. We found that five patients in
this cohort were Cw7 homozygous, and four other patients were
heterozygous for Cw7. The frequency of Cw7 homozygosity
observed in this cohort was 31.3% (95% confidence limits, 11.0
and 58.7%), which was significantly higher than that predicted by
using data from the general population adjusted for ethnic group
(8.6%; P¼0.009 by binomial exact test) (Allele Frequencies in
Worldwide Populations Website, 2006). Cw7 is a member of the
HLA-C
Asn80 allotypes. Cancer susceptibility in individuals homo-
zygous for HLA-C
Asn80, as well as protective effect by HLA-C
Lys80,
Table 1 Characteristics of 16 consecutive patients who underwent autologous HCT and were grouped by their numbers of inhibitory KIR–HLA
receptor–ligand mismatched pairs
Disease
Indication
for HCT
Disease
status at the
time of HCT
No. of
CD133
+ cells
in the graft
( 10
6kg
 1)
Natural
cytotoxicity
(%)
a HLA-Bw HLA-C
KIR
mismatch
a Outcome
NB Stage 4 VGPR 7.9 32.0 6/6 Asn80/Asn80 2DL1, 3DL1 Alive, NED
HD Relapse PR 5.5 13.1 6/6 Asn80/Asn80 2DL1, 3DL1 Alive, NED
HD Relapse CR 4.8 35.0 6/6 Asn80/Asn80 2DL1, 3DL1 Alive, NED
HD Relapse PR 5.0 16.8 6/6 Asn80/Asn80 2DL1, 3DL1 Alive, NED
NB Stage 4 VGPR 7.6 13.5 4/6 Asn80/Asn80 2DL1 Alive, NED
NHL Relapse PR 2.1 ND 6/6 Asn80/Lys80 3DL1 Alive, NED
NHL Relapse PR 2.2 31.0 6/6 Asn80/Lys80 3DL1 Alive, NED
NB Stage 4 VGPR 8.0 15.9 6/6 Asn80/Asn80 3DL1 Died of PD
NHL Relapse PR 5.9 15.6 4/6 Lys80/Lys80 2DL3 Died of PD
PNET Metastasis CR 5.3 16.5 4/6 Asn80/Asn80 2DL1 Died of PD
DSRCT Metastasis CR 5.4 18.4 4/6 Asn80/Lys80 None Alive, NED
NHL Relapse PR 2.5 ND 4/6 Asn80/Lys80 None Died of PD
ES Relapse PR 3.8 26.8 4/6 Asn80/Lys80 None Died of PD
NB Stage 4 VGPR 7.8 17.7 4/4 Asn80/Lys80 None Died of PD
NB Stage 4 PR 6.0 ND 6/6 Asn80/Lys80 None Died of PD
NB Stage 4 VGPR 8.0 15.0 4/6 Asn80/Lys80 None Died of PD
Abbreviations: CR¼complete response; DSRBT¼desmoplastic small round cell tumour; ES¼Ewing’s sarcoma; HD¼Hodgkin’s disease; NB¼neuroblastoma; ND¼not done;
NED¼no evidence of disease; NHL¼non-Hodgkin’s lymphoma; PD¼progressive disease; PNET¼primitive neuroectodermal tumour; PR¼partial response; VGPR¼very
good partial response.
aNatural cytotoxicity indicates the specific lysis of K562 cells by blood mononuclear cells post-HCT and is used for the analysis of the cytotoxicity model;
KIR–HLA mismatch is determined by using the receptor–ligand model.
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2005; Naumova et al, 2005).
DISCUSSION
NK cells in our patients after autologous HCT were primarily
derived from stem/progenitor cells, because mature NK cells were
depleted in vivo and ex vivo by the myeloablative conditioning and
CD133
þ cell–selection procedure. During the period of receptor
acquisition, subsets of NK cells may express a certain inhibitory
KIR with no cognate ligand. Recent studies in healthy mice have
demonstrated that NK cells expressing inhibitory receptors with
no self-ligands exist (Fernandez et al, 2005; Kim et al, 2005). These
cells are hyporesponsive in steady state, because they have not
undergone the ‘licensing’ process (Kim et al, 2005; MacDonald,
2005). However, the hyporesponsive state of these ‘unlicensed’ NK
cells is not permanent, as they can be activated easily in response
to proinflammatory cytokines that activate almost all NK cells
during infection (Biron et al, 1999; Kim et al, 2005). Thus, the
licensing effect was much less prominent among preactivated NK
cells, a finding suggesting that the licensing requirement could be
circumvented in specific situations (Kim et al, 2005). The high-
dose cytotoxic chemotherapy given to our patients may provide
the proinflammatory setting that favours autoreactive NK cells
against tumour cells that express high level of activating ligands
(Castriconi et al, 2004). Worthy of notice, the other transplant
settings in this cohort were also reminiscent of those of our
previous haploidentical cohort in which the KIR–HLA receptor–
ligand model was first established; namely, NK cells were derived
from highly purified stem cells (Leung et al, 2004); mature T cells
and B cells were extensively depleted to provide a lymphopenic
environment (Prlic et al, 2003; Jamieson et al, 2004); and there was
no interference by graft-versus-host disease or its treatment (Lowe
et al, 2003; Cooley et al, 2005). All of these factors may contribute
significantly to the prominent NK cell effects observed in this
study.
The extension of the applicability of the KIR–HLA receptor–
ligand model to autologous HCTs is clinically significant, as the
number of autologous HCTs performed worldwide annually is
twice that of allogeneic HCTs (Center for International Blood and
Marrow Transplant Research (CIBMTR) website, 2006). Haplo-
identical HCTs are performed only in a few centres, whereas
autologous HCTs are offered in almost all the transplantation
centres. Herein, we demonstrated for the first time that patients
with inhibitory KIR–HLA mismatch are at low risk of relapse after
autologous HCT. Other novel observation is that the receptor–
ligand model may be applicable not only to patients with
leukaemia (Leung et al, 2004, Hsu et al, 2005), but also to patients
with lymphoma or solid tumour. One limitation of this study is
that the number of patients was small for each disease category.
Our novel findings, however, should stimulate future studies in
other centres and in larger cohorts with uniform primary diseases.
If confirmed, these results will have significant implications for
prognostication and selection of patients for autologous HCT.
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